SBIR Phase I: An innovative point-of-care device that can rapidly detect and diagnose trauma-induced coagulopathy

该小型企业创新研究（SBIR）第一阶段项目将促进即时设备的技术开发，以测量凝血过程中全血中血小板的作用力。 创伤每年在全球造成近500万人死亡，在美国每小时造成17人死亡。这些死亡是由于创伤诱导的凝血病（TIC）引起的大量失血造成的，这是一种由严重损伤引起的止血（凝血）的全身性损害。目前的SBIR第一阶段奖将资助一项可行性研究，研究通过基于磁性的传感器在凝血过程中测量血小板力的能力。SBIR第一阶段提案的具体技术目标是改进我们基于磁的传感器的信号检测。这些目标的成功完成将使第二阶段的项目，将证明该技术的能力，以检测凝血功能障碍的创伤患者在个性化的基础上，以及患者的抗血小板和/或抗凝药物。该项目更广泛的影响/商业潜力将是减少通常是年轻、有生产力的社会成员的可预防死亡。创伤是年轻人（年龄组1-45岁）死亡的最重要原因，每年花费1350亿美元的医疗费用。创伤患者的过度出血是死亡和医疗费用的主要原因。出血过多往往会因凝血功能障碍而加重，凝血功能障碍是患者的无能吗？的血液凝固和适当密封出血的伤口。目前，急性创伤引起的凝血功能障碍（TIC）发生在四分之一的严重创伤病例，但很难发现和治疗。因此，急诊科医生必须作出半盲决定，输血产品或药物管理的病人，以停止出血的基础上，他们的培训，过去的经验，和模糊的临床指南，并必须采取行动，他们的决定内？黄金时间？(i.e.受伤后大约60分钟），以最大可能地挽救生命、降低发病率并降低医院成本。

This Small Business Innovation Research (SBIR) Phase I project will facilitate technological development of a point-of-care device to measure the forces of platelets from whole blood during clotting. Trauma accounts for nearly 5 million deaths per year worldwide and 17 deaths per hour in the U.S. These deaths arise from an extensive loss of blood due to trauma-induced coagulopathy (TIC), which is a systemic impairment of hemostasis (blood clotting) caused by severe injury. The current SBIR Phase I award will fund a feasibility study on the ability to measure platelet forces during coagulation by a magnetic-based sensor. The specific technical goal of this SBIR Phase I proposal is to improve the signal detection of our magnetic-based sensor. Successful completion of these objectives will enable a Phase II project that will demonstrate the ability of this technology to detect clotting dysfunction in trauma patients on a personalized basis, as well as patients on anti-platelet and or anti-coagulation medications. The broader impact/commercial potential of this project will be to reduce preventable deaths of often young, productive members of society. Trauma is the most imporatn cause of death among young people (age group 1-45 years) and costs $135B in healthcare dollars annually. Excessive bleeding in a trauma patient is a major reason for deaths and medical costs. Excessive bleeding is often made worse by coagulopathy, which is the inability of a patient?s blood to coagulate and properly seal bleeding wounds. Currently, acute trauma-induced coagulopathy (TIC) occurs in 1 in 4 severe trauma cases, but is hard to detect and treat. As a consequence, an emergency department physician must make a semi-blind decision on which transfusion products or drugs to administer to a patient in order to stop the bleeding based upon their training, past experience, and vague clinical guidelines and must act upon their decision within the ?golden hour? (i.e. roughly 60 minutes after injury) to have the best likelihood to save lives, reduce morbidity, and reduce hospital costs.